Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer

Bibliography

• MRebecca Siegel, PJiemin Ma, MZhaohui Zou, DAhmedin Jemal. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9–29
   PubMed Web of Science ®Google Scholar
• GRProut, VFMarshall. The prognosis with untreated bladder tumors. Cancer 1956;9(3):551–8
   PubMed Web of Science ®Google Scholar
• SGupta, AMahipal. Role of systemic chemotherapy in urothelial urinary bladder cancer. Cancer Contr 2013;20(3):200–10
   PubMedGoogle Scholar
• JPStein, DGSkinner. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24(3):296–304
   PubMed Web of Science ®Google Scholar
• DRaghavan. Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol Oncol 2003;21(6):468–74
   PubMed Web of Science ®Google Scholar
• PBassi, GDFerrante, NPiazza, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161(5):1494–7
   PubMed Web of Science ®Google Scholar
• JPStein, GLieskovsky, RCote, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19(3):666–75
   PubMed Web of Science ®Google Scholar
• JASmithJr, EDCrawford, JCParadelo, et al. Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a phase III intergroup study. J Urol 1997;157(3):805–8
   PubMed Web of Science ®Google Scholar
• CLVale. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48(2):202–5
   PubMed Web of Science ®Google Scholar
• CLVale. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 2005;48(2):189–99
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines: bladder cancer [Internet]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#bladder
   Google Scholar
• AStenzl, NCCowan, MDe Santis, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59(6):1009–18
   PubMed Web of Science ®Google Scholar
• KADavid, MIMilowsky, JRitchey, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the national cancer data base. J Urol 2007;178(2):451–4
   PubMed Web of Science ®Google Scholar
• MPPorter, MCKerrigan, BMKDonato, SDRamsey. Patterns of use of systemic chemotherapy for medicare beneficiaries with urothelial bladder cancer. Urol Oncol 2011;29(3):252–8
   PubMed Web of Science ®Google Scholar
• AFeifer, JTaylor, MShouery, et al. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive transitional cell carcinoma of the bladder: Phase I. J Clin Oncol 2011;29:7
   Web of Science ®Google Scholar
• ABApolo, JWKim, BHBochner, et al. Examining the management of muscle-invasive bladder cancer by medical oncologists in the united states. Urol Oncol 2014;32(5):637–44
   PubMed Web of Science ®Google Scholar
• ADash, MDGalsky, AJVickers, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107(3):506–13
   PubMed Web of Science ®Google Scholar
• UFedeli, SAFedewa, EMWard. Treatment of muscle invasive bladder cancer: evidence from the national cancer database, 2003 to 2007. J Urol 2011;185(1):72–8
   PubMed Web of Science ®Google Scholar
• LMPasetto, MRD’Andrea, AABrandes, et al. The development of platinum compounds and their possible combination. Crit Rev Oncol Hematol 2006;60(1):59–75
   PubMed Web of Science ®Google Scholar
• FMBalis, JSHolcenberg, WABleyer. Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet 1983;8(3):202–32
   PubMed Web of Science ®Google Scholar
• PJO’Dwyer, JPStevenson, SWJohnson. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000;59(Suppl 4):19–27
   PubMedGoogle Scholar
• WPlunkett, PHuang, VGandhi. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995;6(Suppl 6):7–13
   PubMed Web of Science ®Google Scholar
• WPlunkett, PHuang, CESearcy, VGandhi. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 1996;23(5 Suppl 10):3–15
   PubMed Web of Science ®Google Scholar
• JLAbbruzzese, RGrimewald, EWeeks, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9(3):491–8
   PubMed Web of Science ®Google Scholar
• WMStadler, TKuzel, BRoth, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15(11):3394–8
   PubMed Web of Science ®Google Scholar
• CFPollera, ACeribelli, MCrecco, FCalabresi. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994;5(2):182–4
   PubMed Web of Science ®Google Scholar
• VLorusso, CFPollera, MAntimi, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 1998;34(8):1208–12
   PubMed Web of Science ®Google Scholar
• MAMoufarij, DRPhillips, CCullinane. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003;63(4):862–9
   PubMed Web of Science ®Google Scholar
• CJAVan Moorsel, HMPinedo, GVeerman, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non small-cell lung cancer cell lines. Br J Cancer 1999;80(7):981–90
   PubMed Web of Science ®Google Scholar
• GJPeters, AMBergman, VWTRuiz Van Haperen, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995;22(4 Suppl 11):72–9
   PubMed Web of Science ®Google Scholar
• MWasif Saif, EChu. Antimetabolites. In: VTDeVita, TLawrence, SARosenberg, editors. DeVita, Hellman, and Rosenberg’s cancer: principles & practice of oncology. 9th edition. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, USA; 2011
   Google Scholar
• BBannwarth, FPéhourcq, TSchaeverbeke, JDehais. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30(3):194–210
   PubMed Web of Science ®Google Scholar
• AYagoda. Chemotherapy of urothelial tract tumors. Cancer 1987;60(3 Suppl):574–85
   PubMed Web of Science ®Google Scholar
• SBKaye, DMcWhinnie, AHart, et al. The treatment of advanced bladder cancer with methotrexate and cis-platinum-a pharmacokinetic study. Eur J Cancer Clin Oncol 1984;20(2):249–52
   PubMedGoogle Scholar
• ISJohnson, JGArmstrong, MGorman, JPBurnettJr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963;23:1390–427
   PubMed Web of Science ®Google Scholar
• XZhou, RRahmani. Preclinical and clinical pharmacology of vinca alkaloids. Drugs 1992;44(Suppl 4):1–16
   PubMedGoogle Scholar
• MSBlumenreich, AYagoda, RBNatale, RCWatson. Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 1982;50(3):435–8
   PubMed Web of Science ®Google Scholar
• TAhmed, AYagoda, BNeedles, et al. Vinblastine and methotrexate for advanced bladder cancer. J Urol 1985;133(4):602–4
   PubMed Web of Science ®Google Scholar
• DAGewirtz. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57(7):727–41
   PubMed Web of Science ®Google Scholar
• JRobert, LGianni. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;17:219–52
   PubMedGoogle Scholar
• SSchwartz, AYagoda, RBNatale, et al. Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors. J Urol 1983;130(4):681–4
   PubMed Web of Science ®Google Scholar
• JAMartinez-Pineiro, MGMartin, FArocena, et al. Original articles: bladder cancer: neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995;153(3 Suppl):964–73
   PubMed Web of Science ®Google Scholar
• DMAWallace, DRaghavan, KAKelly, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991;67(6):608–15
   PubMedGoogle Scholar
• P-Malmström, ERintala, RWahlqvist, et al. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: nordic cystectomy trial I. J Urol 1996;155(6):1903–6
   PubMed Web of Science ®Google Scholar
• ASherif, ERintala, OMestad, et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer: nordic cystectomy trial 2. Scand J Urol Nephrol 2002;36(6):419–25
   PubMed Web of Science ®Google Scholar
• ASherif, LHolmberg, ERintala, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two nordic studies. Eur Urol 2004;45(3):297–303
   PubMed Web of Science ®Google Scholar
• Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999;354(9178):533–40
   PubMed Web of Science ®Google Scholar
• GGriffiths. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29(16):2171–7
   PubMed Web of Science ®Google Scholar
• AYagoda. Chemotherapy for advanced urothelial cancer. Semin Urol 1983;1(1):60–74
   PubMedGoogle Scholar
• CNSternberg, AYagoda, HIScher, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985;133(3):403–7
   PubMed Web of Science ®Google Scholar
• CNSternberg, AYagoda, HIScher, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989;64(12):2448–58
   PubMed Web of Science ®Google Scholar
• PJLoehrerSr, LHEinhorn, PJElson, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 1992;10(7):1066–73
   PubMed Web of Science ®Google Scholar
• CJLogothetis. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050–5
   PubMed Web of Science ®Google Scholar
• HBGrossman, RBNatale, CMTangen, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349(9):859–66
   PubMed Web of Science ®Google Scholar
• PMDodd, JAMccaffrey, MMazumdar, et al. Evaluation of drug delivered and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer. Cancer Invest 2000;18(7):626–34
   PubMed Web of Science ®Google Scholar
• HIScher, NLGeller, TCurley, YToo. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 1993;11(3):400–7
   PubMed Web of Science ®Google Scholar
• NMiyanaga, HAkaza, TShimazui, et al. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer. Cancer Chemother Pharmacol 1994;35(1 Suppl):S5–8
   Google Scholar
• JLGabrilove, AJakubowski, HScher, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318(22):1414–22
   PubMed Web of Science ®Google Scholar
• ADSeidman, HIScher, JLGabrilove, et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. J Clin Oncol 1993;11(3):408–14
   PubMed Web of Science ®Google Scholar
• PJLoehrerSr, PElson, RDreicer, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an eastern cooperative oncology group trial. J Clin Oncol 1994;12(3):483–8
   PubMed Web of Science ®Google Scholar
• CJLogothetis, LDFinn, TSmith, et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 1995;13(9):2272–7
   PubMed Web of Science ®Google Scholar
• CNSternberg, PHMDe Mulder, ATVan Oosterom, et al. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol 1993;4(5):403–7
   PubMed Web of Science ®Google Scholar
• CNSternberg, PHMDe Mulder, JHSchornagel, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol no. 30924. J Clin Oncol 2001;19(10):2638–46
   PubMed Web of Science ®Google Scholar
• CNSternberg, PDe Mulder, JHSchornagel, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42(1):50–4
   PubMed Web of Science ®Google Scholar
• ERPlimack, JHHoffman-Censits, RViterbo, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014;32(18):1895–901
   PubMed Web of Science ®Google Scholar
• TKChoueiri, SJacobus, JBellmunt, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;32(18):1889–94
   PubMed Web of Science ®Google Scholar
• HVon der Maase, SWHansen, JTRoberts, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77
   PubMed Web of Science ®Google Scholar
• HVon Der Maase, LSengelov, JTRoberts, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23(21):4602–8
   PubMed Web of Science ®Google Scholar
• ASantoro, HSoto Parra, RCavina, et al. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol 2002;13(7):1080–6
   PubMed Web of Science ®Google Scholar
• ADash, JAPettus IV, HWHerr, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008;113(9):2471–7
   PubMed Web of Science ®Google Scholar
• DHerchenhorn, RDienstmann, FAPeixoto, et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol 2007;33(5):630–8
   PubMedGoogle Scholar
• JHoffman-Censits, YWong, TLi, et al. Dose intensity of cisplatin and gemcitabine (CG) for muscle invasive urothelial bladder cancer (MIUBC) in the neoadjuvant versus adjuvant settings: the fox chase cancer center (FCCC) experience. J Clin Oncol 2009;27(Suppl):abstract e16012
   Google Scholar
• EPlimack, JHoffman-Censits, AKutikov, et al. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study. J Clin Oncol 2014;32(5 Suppl):abstract 4513
   Google Scholar
• LCMalmrose, SLGray, CFPieper, et al. Measured versus estimated creatinine clearance in a high-functioning elderly sample: macArthur foundation study of successful aging. J Am Geriatr Soc 1993;41(7):715–21
   PubMed Web of Science ®Google Scholar
• GVRaj, AIasonos, HHerr, SMDonat. Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol 2006;24(19):3095–100
   PubMed Web of Science ®Google Scholar
• MDGalsky, NMHahn, JRosenberg, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12(3):211–14
   PubMed Web of Science ®Google Scholar
• SAHussain, DDStocken, PRiley, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer 2004;91(5):844–9
   PubMed Web of Science ®Google Scholar
• SAHussain, DHPalmer, BLloyd, et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett 2012;3(4):855–9
   PubMed Web of Science ®Google Scholar
• ARossi, MDi Maio, PChiodini, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30(14):1692–8
   PubMed Web of Science ®Google Scholar
• JJiang, XLiang, XZhou, et al. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007;57(3):348–58
   PubMed Web of Science ®Google Scholar
• JBellmunt, ARibas, NEres, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997;80(10):1966–72
   PubMed Web of Science ®Google Scholar
• RPetrioli, BFrediani, AManganelli, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study. Cancer 1996;77(2):344–51
   PubMed Web of Science ®Google Scholar
• LDogliotti, GCartenì, SSiena, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007;52(1):134–41
   PubMed Web of Science ®Google Scholar
• RDreicer, JManola, BJRoth, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: a trial of the eastern cooperative oncology group. Cancer 2004;100(8):1639–45
   PubMed Web of Science ®Google Scholar
• MDGalsky, GJChen, WKOh, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 2012;23(2):406–10
   PubMed Web of Science ®Google Scholar
• RWdeVere White, PNLaraSr, BGoldman, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II southwest oncology group trial (S0219). J Urol 2009;181(6):2476–81
   PubMed Web of Science ®Google Scholar
• ABApolo, HBGrossman, DBajorin, et al. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the society of urologic oncology annual meeting. Urol Oncol 2012;30(6):772–80
   PubMed Web of Science ®Google Scholar
• CSternberg, ISkoneczna, JKerst, et al. Final results of EORTC intergroup randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 2014;32(5 Suppl):abstract 4500
   Google Scholar
• UChaudhary, AGolshayan, ABrisendine, et al. Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy (RC) in patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder. J Clin Oncol 2011;29(Suppl 7):abstract 276
   Google Scholar
• ASiefker-Radtke, AKamat, PCorn, et al. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the M. D. Anderson Cancer Center. J Clin Oncol 2012;30(Suppl 5):abstract 261
   Google Scholar
• MDGalsky, NMHahn, TPowles, et al. Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 2013;11(2):175–81
   PubMed Web of Science ®Google Scholar
• RMBambury, JERosenberg. Actionable mutations in muscle-invasive bladder cancer. Curr Opin Urol 2013;23(5):472–8
   PubMed Web of Science ®Google Scholar